Related Experiment Video
Updated: Jun 30, 2026

Efficient Purification and LC-MS/MS-based Assay Development for Ten-Eleven Translocation-2 5-Methylcytosine Dioxygenase
Published on: October 15, 2018
Methylation-associated silencing of TU3A in human cancers
Yasuo Awakura1, Eijiro Nakamura, Noriyuki Ito
1Department of Urology, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.
Abstract:
TU3A, located on 3p21.1, was originally identified as a candidate tumor suppressor gene in renal cell carcinoma (RCC). Recently, down-regulation of TU3A expression has been reported not only in RCC but also in other types of cancers. However, no studies have evaluated the mechanism underlying TU3A inactivation. In the present study, we first examined the expression and promoter CpG island methylation of TU3A in RCC. TU3A mRNA was slightly or not expressed in 3 RCC cell lines (ACHN, Caki-1 and NC65). Bisulfite sequencing of the TU3A promoter and treatment of the RCC cell lines with 5-aza-2'-deoxycytidine and/or trichostatin A revealed an association between TU3A expression and promoter hypermethylation. Next, we analyzed TU3A methylation in primary RCC by using combined bisulfite restriction analysis. Mean methylated fraction was 19.2% (range: 0-57.3%) in 53 conventional RCCs and 2.3% (range: 0-12.7%) in 24 corresponding normal kidneys. We defined a methylation fraction of >20% as hypermethylation. TU3A hypermethylation was detected in 22 (41.5%) of 53 RCCs and significantly associated with advanced tumor stage (>T2 vs. T1 and T2: P=0.005, > or = N1 or M1 vs. N0M0: P=0.001) and poor disease-specific survival (P=0.0038). Furthermore, we observed promoter hyper-methylation of TU3A in several types of cancer cell lines and primary cancers of the bladder and testis. To our knowledge, the present study is the first to demonstrate the epigenetic inactivation of TU3A in human cancers. The findings of this study warrant further study to investigate the role of TU3A methylation in cancer development.
Insights
The tumor suppressor gene TU3A is epigenetically silenced by promoter hypermethylation in renal cell carcinoma (RCC), correlating with advanced stages and poor survival. This methylation was also observed in other cancers, suggesting a broader role in tumorigenesis.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- TU3A, a candidate tumor suppressor gene, shows down-regulated expression in various cancers, including renal cell carcinoma (RCC).
- The mechanisms underlying TU3A inactivation, particularly in RCC, remained largely unexplored prior to this study.
Purpose of the Study:
- To investigate the expression and promoter CpG island methylation of TU3A in RCC.
- To determine the association between TU3A hypermethylation and clinicopathological features and survival in RCC patients.
- To explore TU3A methylation in other cancer types.
Main Methods:
- Analysis of TU3A mRNA expression in RCC cell lines.
- Bisulfite sequencing and 5-aza-2'-deoxycytidine/trichostatin A treatment to assess promoter methylation in RCC cell lines.
- Combined bisulfite restriction analysis (COBRA) to evaluate TU3A methylation in primary RCC and normal kidney tissues.
- Correlation analysis between TU3A methylation status and clinicopathological data, including tumor stage and patient survival.
- Examination of TU3A promoter methylation in other cancer cell lines and primary tumors.
Main Results:
- TU3A mRNA expression was low or absent in examined RCC cell lines.
- TU3A expression inversely correlated with promoter hypermethylation in RCC cell lines.
- Hypermethylation of the TU3A promoter was detected in 41.5% of primary RCCs, significantly higher than in normal kidney tissues.
- TU3A hypermethylation was significantly associated with advanced tumor stage (T stage, N stage, M stage) and poorer disease-specific survival in RCC patients.
- Promoter hypermethylation of TU3A was also observed in bladder and testis cancer cell lines and primary tumors.
Conclusions:
- Epigenetic inactivation of TU3A through promoter hypermethylation is a mechanism contributing to RCC development.
- TU3A hypermethylation serves as a potential biomarker for advanced RCC and poor prognosis.
- The findings suggest that TU3A epigenetic silencing may play a role in the pathogenesis of multiple human cancers.
Related Concept Videos
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
MicroRNAs
MicroRNAs
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

